Vasculitis, also called Perleche, is an inflammation of the linings of the small veins in the skin. Common symptoms are redness that grows worse with movement or any physical activity, usually around the ankles and legs. The inflammation may spread to the neck, shoulders, arms, and even down the arms of the patient. Although some patients do not suffer any symptoms, many others will experience sudden and inexplicable pain that can even be painful, particularly at night while rising from bed. While most cases of vasculitis include no known causes, there are several conditions that can trigger the inflammation, including diabetes mellitus, obesity, smoking, anti-inflammatory drugs, and steroids.
When considering vasculitis treatment, it is important to understand that the condition only affects the skin and not the major organs involved in the digestive tract. While the typical course of treatment for acute cases of vasculitis can include antibiotic medications, surgery, and other procedures, it is also possible for more invasive treatments to be required in order to treat this condition. Several different types of vasculitis are included among the different cardiovascular diseases and the main classification criteria are based on their pathogenesis, clinical presentation, and symptoms.
Doctors use a variety of different methods to diagnose and treat vasculitis. They usually perform a physical exam, rule out infections, and perform blood tests to check for clotting issues. The doctor may also order a couple of blood tests in order to rule out angina, coronary artery disease, and peripheral arterial disease as causes of the symptoms. If all of these potential causes are ruled out, then the doctor will begin to evaluate possible vasculitis treatment options. Recently, in September 2020, ChemoCentryx Inc. received the U.S. Food and Drug Administration (FDA) approval for its new drug application (NDA) avacopan indicated for the treatment of ANCA-associated vasculitis.
No comments:
Post a Comment